
BMO Capital Markets | Baird | BofA Securities | Huntington Capital Markets | ||||||
Jefferies | J.P. Morgan | KeyBanc Capital Markets | |||||||
M&T Securities | Raymond James | RBC Capital Markets | Regions Securities LLC | ||||||
Wells Fargo Securities | |||||||||

BMO Capital Markets | Baird | BofA Securities | Huntington Capital Markets | ||||||
Jefferies | J.P. Morgan | KeyBanc Capital Markets | |||||||
M&T Securities | Raymond James | RBC Capital Markets | Regions Securities LLC | ||||||
Wells Fargo Securities | |||||||||
• | the ability of our tenants, managers, and borrowers to successfully operate our properties and to meet and/or perform their obligations under the agreements we have entered into with them, including without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; |
• | the impact of unstable market and economic conditions; |
• | the impact of healthcare reform legislation, including reimbursement rates and potential minimum staffing level requirements, on the operating results and financial conditions of our tenants, managers, and borrowers; |
• | the consequences of bankruptcy, insolvency or financial deterioration of our tenants, managers and borrowers; |
• | the ability and willingness of our tenants, managers and borrowers to renew their agreements with us, and our ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant or manager; |
• | the risk that we may have to incur additional impairment charges related to our assets held for sale if we are unable to sell such assets at the prices we expect; |
• | the impact of public health crises; |
• | the availability of and the ability to identify (a) tenants and managers who meet our credit and operating standards, and (b) suitable acquisition opportunities and the ability to acquire and lease the respective properties to such tenants on favorable terms; |
• | the intended benefits of our acquisition of Care REIT plc (“Care REIT”) may not be realized, and the additional risks we will be subject to from our investment in Care REIT and any other international investments; |
• | the additional operational and legal risks associated with our properties managed in a RIDEA (as defined below) structure; |
• | the impact of the unfavorable resolution of litigation or disputes and rising liability and insurance costs as a result thereof or other market factors; |
• | the ability to retain our key management personnel; |
• | the ability to maintain our status as a real estate investment trust (“REIT”); |
• | changes in the U.S. and U.K. tax law and other state, federal or local laws, whether or not specific to REITs; |
• | the ability to generate sufficient cash flows to service our outstanding indebtedness; |
• | access to debt and equity capital markets; and |
• | fluctuating interest and currency rates. |
• | our Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the SEC on February 12, 2026); |
• | the portions of our Definitive Proxy Statement on Schedule 14A that are incorporated by reference into Part III of our Annual Report on Form 10-K for the year ended December 31, 2024 (filed with the SEC on March 7, 2025); |
• | the description of our common stock, par value $0.01 per share, contained in Exhibit 4.4 of our Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the SEC on February 12, 2026), and any amendments or reports filed for the purpose of updating such description. |
• | “business combination” provisions that, subject to limitations, prohibit certain business combinations between us and an “interested stockholder” (defined generally as any person who beneficially owns 10% or more of the voting power of our shares or an affiliate thereof) for five years after the most recent date on which the stockholder becomes an interested stockholder, and thereafter impose special appraisal rights and special stockholder voting requirements on these combinations; and |
• | “control share” provisions that provide that “control shares” of our company (defined as shares which, when aggregated with other shares owned by the acquiring person or in respect of which the acquiring person is entitled to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquiring person to exercise one of three increasing ranges of voting power in electing directors) acquired in a “control share acquisition” (defined as the direct or indirect acquisition of ownership or control of “control shares”) have no voting rights except to the extent approved by our stockholders by the affirmative vote of at least two-thirds of all the votes entitled to be cast on the matter, excluding all interested shares. |
• | a shift in our investor base; |
• | our quarterly or annual earnings, or those of other comparable companies; |
• | actual or anticipated fluctuations in our operating results; |
• | our ability to obtain financing as needed, including through potential future equity or debt issuances; |
• | increases in market interest rates, which may lead investors in our common stock to demand a higher yield, and would result in increased interest expense on our debt; |
• | changes in laws and regulations affecting our business; |
• | changes in accounting standards, policies, guidance, interpretations or principles; |
• | announcements by us or our competitors of significant investments, acquisitions or dispositions; |
• | the failure of securities analysts to cover our common stock; |
• | changes in earnings estimates by securities analysts or our ability to meet those estimates; |
• | the operating performance and stock price of other comparable companies; |
• | changes in our dividend policy; |
• | impairment charges affecting the carrying value of one or more of our investments; |
• | issuances of additional equity securities, including pursuant to this offering, or sales of our common stock by directors or our management team; |
• | overall market fluctuations; and |
• | general economic or political conditions and other external factors. |
• | in such Forward Purchaser’s commercially reasonable judgment, it or its affiliate (x) is unable to hedge its exposure under such forward sale agreement because insufficient shares of our common stock have been made available for borrowing by securities lenders or (y) would incur a stock loan cost in excess of a specified threshold to hedge in a commercially reasonable manner its exposure under such forward sale agreement; |
• | we declare any distribution, issue or dividend on shares of our common stock (a) payable in cash in excess of specified amounts (unless it is an extraordinary dividend), (b) that constitutes an extraordinary dividend under the forward sale agreement, (c) payable in securities of another company as a result of a spin-off or similar transaction, or (d) payable in any other type of securities (other than our common stock), rights, warrants or other assets for payment at less than the prevailing market price; |
• | an event is announced that, if consummated, would result in a specified extraordinary event (including certain mergers or tender offers, as well as certain events involving our nationalization, our insolvency or a delisting of our common stock) or the occurrence of a change in law or disruption in such Forward Purchaser’s ability to hedge its exposure under the relevant forward sale agreement; |
• | certain other events of default or termination events occur, including, among others, any material misrepresentation made in connection with such forward sale agreement (each as more fully described in each forward sale agreement); or |
• | certain ownership thresholds applicable to such Forward Purchaser and its affiliates are exceeded. |
• | return shares of our common stock to securities lenders in order to unwind such Forward Purchaser’s hedge (after taking into consideration any shares of our common stock to be delivered by us to such Forward Purchaser, if applicable, in the case of net share settlement); and |
• | if applicable, in the case of net share settlement, deliver shares of our common stock to us to the extent required in settlement of such forward sale agreement. |
• | return shares of our common stock to securities lenders in order to unwind such Forward Purchaser’s hedge (after taking into consideration any shares of our common stock to be delivered by us to such Forward Purchaser, if applicable, in the case of net share settlement); and |
• | if applicable, in the case of net share settlement, deliver shares of our common stock to us to the extent required in settlement of such forward sale agreement. |
• | in such Forward Purchaser’s commercially reasonable judgment, it or its affiliate (x) is unable to hedge its exposure under such forward sale agreement because insufficient shares of our common stock have been made available for borrowing by securities lenders or (y) would incur a stock loan cost in excess of a specified threshold to hedge in a commercially reasonable manner its exposure under such forward sale agreement; |
• | we declare any distribution, issue or dividend on shares of our common stock (a) payable in cash in excess of specified amounts (unless it is an extraordinary dividend), (b) that constitutes an extraordinary dividend under the forward sale agreement, (c) payable in securities of another company as a result of a spin-off or similar transaction, or (d) payable in any other type of securities (other than our common stock), rights, warrants or other assets for payment at less than the prevailing market price; |
• | an event is announced that, if consummated, would result in a specified extraordinary event (including certain mergers or tender offers, as well as certain events involving our nationalization, our insolvency or a delisting of our common stock) or the occurrence of a change in law or disruption in such Forward Purchaser’s ability to hedge its exposure under the relevant forward sale agreement; |
• | certain other events of default or termination events occur, including, among others, any material misrepresentation made in connection with such forward sale agreement (each as more fully described in each forward sale agreement); or |
• | certain ownership thresholds applicable to such Forward Purchaser and its affiliates are exceeded. |

• | shares of common stock; |
• | shares of preferred stock; |
• | warrants to purchase common stock and/or preferred stock; |
• | rights to purchase common stock and/or preferred stock; |
• | units consisting of two or more of these classes or series of securities; and |
• | debt securities. |
• | our Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the SEC on February 12, 2026); |
• | the portions of our Definitive Proxy Statement on Schedule 14A that are incorporated by reference into Part III of our Annual Report on Form 10-K for the year ended December 31, 2024 (filed with the SEC on March 7, 2025); and |
• | the description of our common stock, par value $0.01 per share, contained in Exhibit 4.4 of our Annual Report on Form 10-K for the year ended December 31, 2025 (filed with the SEC on February 12, 2026), and any amendments or reports filed for the purpose of updating such description. |
• | the ability of our tenants, managers, and borrowers to successfully operate our properties and to meet and/or perform their obligations under the agreements we have entered into with them, including without limitation, their respective obligations to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities; |
• | the impact of unstable market and economic conditions; |
• | the impact of healthcare reform legislation, including reimbursement rates and potential minimum staffing level requirements, on the operating results and financial conditions of our tenants, managers, and borrowers; |
• | the consequences of bankruptcy, insolvency or financial deterioration of our tenants, managers and borrowers; |
• | the ability and willingness of our tenants, managers and borrowers to renew their agreements with us, and our ability to reposition our properties on the same or better terms in the event of nonrenewal or in the event we replace an existing tenant or manager; |
• | the risk that we may have to incur additional impairment charges related to our assets held for sale if we are unable to sell such assets at the prices we expect; |
• | the impact of public health crises; |
• | the availability of and the ability to identify (a) tenants and managers who meet our credit and operating standards, and (b) suitable acquisition opportunities and the ability to acquire and lease the respective properties to such tenants on favorable terms; |
• | the intended benefits of our acquisition of Care REIT plc (“Care REIT”) may not be realized, and the additional risks we will be subject to from our investment in Care REIT and any other international investments; |
• | the additional operational and legal risks associated with our properties managed in a RIDEA (as defined below) structure; |
• | the impact of the unfavorable resolution of litigation or disputes and rising liability and insurance costs as a result thereof or other market factors; |
• | the ability to retain our key management personnel; |
• | the ability to maintain our status as a real estate investment trust (“REIT”); |
• | changes in the U.S. and U.K. tax law and other state, federal or local laws, whether or not specific to REITs; |
• | the ability to generate sufficient cash flows to service our outstanding indebtedness; |
• | access to debt and equity capital markets; and |
• | fluctuating interest and currency rates. |
(in thousands) | As of December 31, 2025 | ||
Assets: | |||
Cash and cash equivalents | $159,343 | ||
Other assets | 2,414,686 | ||
Intercompany receivables from non-guarantor subsidiaries | 649,032 | ||
Total assets | $3,223,061 | ||
Liabilities: | |||
Senior unsecured notes payable, net(1) | $397,816 | ||
Senior unsecured term loan, net(1) | 496,404 | ||
Other liabilities | 148,136 | ||
Total liabilities | $1,042,356 | ||
(1) | The senior unsecured notes and senior unsecured term loan are obligations of the Operating Partnership and are guaranteed, jointly and severally, on an unsecured basis, by CareTrust REIT and substantially all of its other subsidiaries. |
(in thousands) | Year Ended December 31, 2025 | ||
Total revenues | $217,742 | ||
Total expenses | 128,892 | ||
Total gain | 51,739 | ||
Net income | $140,589 | ||
Net intercompany interest income | $26,009 | ||
• | the title, designation, number of shares and stated value of the preferred stock; |
• | the price at which the preferred stock will be issued; |
• | the dividend rates, if any (or method of calculation), whether that rate is fixed or variable or both, and the dates on which dividends will be payable, whether those dividends will be cumulative or noncumulative and, if cumulative, the dates from which dividends will begin to cumulate; |
• | the dates on which the preferred stock will be subject to redemption and the applicable redemption prices; |
• | any redemption or sinking fund provisions; |
• | the convertibility or exchangeability of the preferred stock; |
• | if other than United States dollars, the currency or currencies (including composite currencies) in which the preferred stock is denominated and/or in which payments will or may be payable; |
• | the method by which amounts in respect of the preferred stock may be calculated and any commodities, currencies or indices, or the value, rate or price relevant to that calculation; |
• | the place where dividends and other payments on the preferred stock are payable and the identity of the transfer agent, registrar and dividend disbursement agent for the preferred stock; |
• | any listing of the preferred stock on any securities exchange; and |
• | any additional dividend, liquidation, redemption, preemption, sinking fund, voting and other rights, preferences, privileges, limitations and restrictions. |
• | any person from beneficially or constructively owning shares of our stock to the extent such beneficial or constructive ownership would result in us being “closely held” under Section 856(h) of the Code or otherwise cause us to fail to qualify as a REIT; |
• | any person from transferring shares of our stock if the transfer would result in shares of our stock being beneficially owned by fewer than 100 persons; |
• | any person from beneficially owning or constructively owning shares of our stock to the extent such ownership would result in us failing to qualify as a “domestically controlled qualified investment entity,” within the meaning of Section 897(h) of the Code; |
• | any person from beneficially or constructively owning shares of our stock to the extent such beneficial or constructive ownership would cause us to own, beneficially or constructively, 9.9% or more of the ownership interests in a tenant (other than a “taxable REIT subsidiary” of ours (as such term is defined in Section 856(l) of the Code)) of our real property within the meaning of Section 856(d)(2)(B) of the Code; and |
• | any person from beneficially or constructively owning shares of our stock to the extent such beneficial or constructive ownership would cause any “eligible independent contractor” that operates a “qualified health care property” on behalf of a “taxable REIT subsidiary” of ours (as such terms are defined in Sections 856(d)(9)(A), 856(e)(6)(D)(i) and 856(l) of the Code, respectively) to fail to qualify as such. |
• | any person who beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock; or |
• | an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner of 10% or more of the voting power of the then outstanding voting stock of the corporation. |
• | 80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and |
• | two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder, voting together as a single class. |
• | one-tenth or more but less than one-third; |
• | one-third or more but less than a majority; or |
• | more than 50%. |
• | a classified board; |
• | a two-thirds vote requirement for removing a director; |
• | a requirement that the number of directors be fixed only by vote of the directors; |
• | a requirement that a vacancy on the board be filled only by the affirmative vote of a majority of the remaining directors in office and such director shall hold office for the remainder of the full term of the class of directors in which the vacancy occurred and until a successor is elected and qualified; and |
• | a majority requirement for the calling of a special meeting of stockholders. |
• | the act or omission of the director or officer was material to the matter giving rise to the proceeding and (i) was committed in bad faith or (ii) was the result of active and deliberate dishonesty; |
• | the director or officer actually received an improper personal benefit in money, property or services; or |
• | in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. |
• | the title of the warrants; |
• | the price or prices at which the warrants will be issued; |
• | the designation, amount and terms of the securities for which the warrants are exercisable; |
• | the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants issued with each other security; |
• | the aggregate number of warrants offered; |
• | any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants; |
• | the price or prices at which the securities purchasable upon exercise of the warrants may be purchased; |
• | if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will be separately transferable; |
• | a discussion of any material U.S. federal income tax considerations applicable to the holding and/or exercise of the warrants; |
• | the date on which the right to exercise the warrants will commence, and the date on which the right will expire; |
• | the maximum or minimum number of warrants that may be exercised at any time; |
• | information with respect to book-entry procedures, if any; and |
• | any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. |
• | the date for determining the persons entitled to participate in the rights distribution; |
• | the aggregate number or amount of underlying securities purchasable upon exercise of the rights and the exercise price; |
• | the aggregate number of rights being issued; |
• | the date, if any, on and after which the rights may be transferable separately; |
• | the date on which the right to exercise the rights commences and the date on which the right expires; |
• | the number of rights outstanding, if any; |
• | a discussion of any material or special U.S. federal income tax considerations applicable to the rights; and |
• | any other terms of the rights, including the terms, procedures and limitations relating to the distribution, exchange and exercise of the rights. |
• | the date, if any, on and after which the units may be transferable separately; |
• | whether we will apply to have the units traded on a securities exchange or securities quotation system; |
• | a discussion of any material or special U.S. federal income tax considerations applicable to the units; and |
• | how, for U.S. federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities. |
• | the identity of the issuer; |
• | the title of the debt securities being offered; |
• | the principal amount being offered, and, if a series, the total amount authorized and the total amount outstanding; |
• | any limit on the aggregate principal amount of the debt securities that may be issued; |
• | whether or not the series of debt securities will be issued in global form and, if so, the identity of the depositary and the terms and conditions, if any, upon which interests in the debt securities may be exchanged; |
• | the date or dates on which the principal of the debt securities is payable; |
• | the principal amount due at maturity, and whether the debt securities will be issued with any original issue discount; |
• | the interest rate(s) at which the debt securities will bear interest, which may be fixed or variable, or the method for determining the rate, the date from which interest will accrue, the dates interest will be payable and the regular record dates for interest payable on any interest payment date or the method for determining such dates; |
• | whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
• | the place where payments of principal (and premium, if any) and interest will be payable, where the debt securities may be surrendered for transfer or exchange and where notices or demands may be served; |
• | the date, if any, after which, the terms and conditions upon which, and the price at which the debt securities may be redeemed, in whole or in part, pursuant to any optional or provisional redemption provisions, and any other applicable terms of those redemption provisions; |
• | provisions for a sinking fund or other provisions that would require the redemption, repayment or purchase of the debt securities, if any; |
• | the terms and conditions, if any, upon which the debt securities of the series will be required to be repurchased at the option of the holders of such debt securities; |
• | the events of default and covenants relevant to the debt securities, including the inapplicability of any event of default or covenant set forth in the indenture relating to the debt securities, or the applicability of any other events of defaults or covenants in addition to the events of default or covenants set forth in the indenture relating to the debt securities; |
• | any provisions for the satisfaction and discharge or defeasance or covenant defeasance of the indenture under which the debt securities are issued; |
• | the denominations in which the issuer will issue the series of debt securities, if other than denominations of $2,000 and any integral multiples of $1,000 in excess thereof; |
• | if other than U.S. dollars, the currency in which the series of debt securities will be denominated; |
• | the identity of the guarantor, if any, of the debt securities and the terms of any such guarantee; and |
• | any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, and any terms which may be required by the issuer or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities. |
• | financial institutions; |
• | insurance companies; |
• | broker-dealers; |
• | regulated investment companies; |
• | partnerships, other pass-through entities and trusts; |
• | persons who hold our stock on behalf of other persons as nominees; |
• | persons who receive our stock as compensation; |
• | persons holding our stock as part of a “straddle,” “hedge,” “conversion transaction,” “synthetic security” or other integrated investment; |
• | persons who are subject to alternative minimum tax; |
• | tax-exempt organizations; and |
• | foreign investors. |
• | We will be taxed at regular corporate rates on any undistributed net taxable income, including undistributed net capital gains. |
• | For taxable years prior to January 1, 2018, we may be subject to the “alternative minimum tax” on our items of tax preference, including any deductions of net operating losses. |
• | If we have net income from prohibited transactions, which are, in general, sales or other dispositions of inventory or property held primarily for sale to customers in the ordinary course of business, other than foreclosure property, such income will be subject to a 100% tax. See “—Prohibited Transactions” and “—Foreclosure Property.” |
• | If we elect to treat property that we acquire in connection with a foreclosure of a mortgage loan or certain leasehold terminations as “foreclosure property,” we may thereby avoid the 100% tax on gain from a resale of that property (if the sale would otherwise constitute a prohibited transaction), but the income from the sale or operation of the property may be subject to corporate income tax at the highest applicable rate (currently 21%). |
• | If we fail to satisfy the 75% gross income test or the 95% gross income test, as discussed below, but nonetheless maintain our qualification to be taxed as a REIT because we satisfy other requirements, we will be subject to a 100% tax on an amount based on the magnitude of the failure, as adjusted to reflect the profit margin associated with our gross income. |
• | If we violate the asset tests (other than certain de minimis violations) or other requirements applicable to REITs, as described below, and yet maintain our qualification to be taxed as a REIT because there is reasonable cause for the failure and other applicable requirements are met, we may be subject to a penalty tax. In that case, the amount of the penalty tax will be at least $50,000 per failure, and, in the case of certain asset test failures, will be determined as the amount of net income generated by the non-qualifying assets in question multiplied by the highest corporate tax rate (currently 21%) if that amount exceeds $50,000 per failure. |
• | If we fail to distribute during each calendar year at least the sum of (1) 85% of our ordinary income for such year, (2) 95% of our capital gain net income for such year and (3) any undistributed net taxable income from prior periods, we will be subject to a nondeductible 4% excise tax on the excess of the required distribution over the sum of (a) the amounts that we actually distributed and (b) the amounts we retained and upon which we paid income tax at the corporate level. |
• | We may be required to pay monetary penalties to the IRS in certain circumstances, including if we fail to meet record-keeping requirements intended to monitor our compliance with rules relating to the composition of a REIT’s stockholders, as described below in “—Requirements for Qualification—General.” |
• | A 100% tax may be imposed on transactions between us and a taxable REIT subsidiary (“TRS”) that do not reflect arm’s-length terms. |
• | If after the effective date of our election to be subject to tax as a REIT, we acquire appreciated assets from a corporation that is not a REIT (i.e., a corporation taxable under subchapter C of the Code) in a transaction in which the adjusted tax basis of the assets in our hands is determined by reference to the adjusted tax basis of the assets in the hands of the subchapter C corporation, we may be subject to tax on such appreciation at the highest corporate income tax rate then applicable if we subsequently recognize gain on a disposition of any such assets during the five-year period following their acquisition from the subchapter C corporation. |
• | The earnings of our TRSs will generally be subject to U.S. federal corporate income tax. |
(1) | that is managed by one or more trustees or directors; |
(2) | the beneficial ownership of which is evidenced by transferable shares, or by transferable certificates of beneficial interest; |
(3) | that would be taxable as a domestic corporation but for its election to be subject to tax as a REIT; |
(4) | that is neither a financial institution nor an insurance company subject to specific provisions of the Code; |
(5) | the beneficial ownership of which is held by 100 or more persons; |
(6) | in which, during the last half of each taxable year, not more than 50% in value of the outstanding stock is owned, directly or indirectly, by five or fewer “individuals” (as defined in the Code to include specified tax-exempt entities); and |
(7) | that meets other tests described below, including with respect to the nature of its income and assets. |
• | The amount of rent is not based in whole or in part on the income or profits of any person. However, an amount we receive or accrue will generally not be excluded from the term “rents from real property” solely because it is based on a fixed-percentage or percentages of receipts or sales; |
• | Neither we nor an actual or constructive owner of 10% or more of our stock actually or constructively owns 10% or more of the interests in the assets or net profits of a noncorporate tenant, or, if the tenant is a corporation (but excluding any TRS), 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of the tenant. Rents we receive from such a tenant that is a TRS of ours, however, will not be excluded from the definition of “rents from real property” as a result of this condition if at least 90% of the space at the property to which the rents relate is leased to third parties, and the rents paid by the TRS are substantially comparable to rents paid by our other tenants for comparable space. Whether rents paid by a TRS are substantially comparable to rents paid by other tenants is determined at the time the lease with the TRS is entered into, extended, and modified, if such modification increases the rents due under such lease. Notwithstanding the foregoing, however, if a lease with a “controlled TRS” is modified and such modification results in an increase in the rents payable by such TRS, any such increase will not qualify as “rents from real property.” For purposes of this rule, a “controlled TRS” is a TRS in which the parent REIT owns stock possessing more than 50% of the voting power or more than 50% of the total value of the outstanding stock of such TRS. In addition, rents we receive from a tenant that also is our TRS will not be excluded from the definition of “rents from real property” as a result of our ownership interest in the TRS if the property to which the rents relate is a qualified lodging facility or a qualified health care property, and such property is operated on behalf of the TRS by a person who is an independent contractor and certain other requirements are met. Our TRSs will be subject to U.S. federal income tax on their income from the operations of these properties; |
• | Rent attributable to personal property that is leased in connection with a lease of real property is not greater than 15% of the total rent received under the lease. If this condition is not met, then the portion of the rent attributable to personal property will not qualify as “rents from real property”; and |
• | We generally do not operate or manage the property or furnish or render services to our tenants, subject to a 1% de minimis and except as provided below. We are permitted, however, to perform directly certain services that are “usually or customarily rendered” in connection with the rental of space for occupancy only and are not otherwise considered “rendered to the occupant” of the property. Examples of these permitted services include the provision of light, heat or other utilities, trash removal and general maintenance of common areas. In addition, we are permitted to employ an independent contractor from whom we derive no revenues (a “TRS”), which may be wholly or partially owned by us, to provide non-customary services to our tenants without causing the rent that we receive from those tenants to fail to qualify as “rents from real property.” |
(1) | the sum of |
(a) | 90% of our REIT taxable income, computed without regard to our net capital gains and the deduction for dividends paid; and |
(b) | 90% of our after tax net income, if any, from foreclosure property (as described below); |
(2) | minus |
(a) | the excess of the sum of specified items of noncash income over 5% of our REIT taxable income, computed without regard to our net capital gain and the deduction for dividends paid. |
• | an individual who is a citizen or resident of the United States; |
• | a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in the United States or under the laws of the United States, or of any state thereof, or the District of Columbia; |
• | an estate, the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or |
• | trust if a U.S. court is able to exercise primary supervision over the administration of such trust and one or more U.S. fiduciaries have the authority to control all substantial decisions of the trust |
• | income retained by the REIT in the prior taxable year on which the REIT was subject to corporate level income tax (less the amount of tax); |
• | dividends received by the REIT from TRSs or other taxable C corporations; or |
• | income in the prior taxable year from sales of “built-in gain” property acquired by the REIT from C corporations in carryover basis transactions (less the amount of corporate tax on such income). |
• | directly to one or more purchasers, including through a specific bidding, auction or other process; |
• | to investors through agents; |
• | directly to agents; |
• | to or through brokers or dealers; |
• | to the public through underwriting syndicates led by one or more managing underwriters; |
• | to one or more underwriters acting alone for resale to investors or to the public; |
• | through a combination of any such methods of sale; or |
• | any other method permitted pursuant to applicable law. |
• | the method of distribution, including the name or names of any underwriters, dealers or agents and the amounts of securities underwritten or purchased by each of them, if any; |
• | the purchase price of the securities and the proceeds to us from the sale; |
• | any over-allotment options under which the underwriters may purchase additional securities from us; |
• | any underwriting discounts and other items constituting compensation to underwriters, dealers or agents; |
• | any public offering price; |
• | any discounts or concessions allowed or reallowed or paid to dealers; or |
• | any securities exchange or market on which the securities offered in the prospectus supplement may be listed. |
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/22/2026 | $44.00 | Mkt Outperform | Citizens JMP |
| 1/9/2026 | $43.00 | Market Perform → Outperform | BMO Capital Markets |
| 11/18/2025 | $42.00 | Buy | UBS |
| 10/1/2025 | $37.00 | Neutral | Cantor Fitzgerald |
| 3/13/2025 | $31.00 | Hold → Buy | Deutsche Bank |
| 1/2/2025 | $34.00 → $26.00 | Neutral → Underperform | Wedbush |
| 12/9/2024 | $34.00 → $32.00 | Outperform → Market Perform | BMO Capital Markets |
| 10/1/2024 | $28.00 → $34.00 | Equal Weight → Overweight | Wells Fargo |
Citizens JMP initiated coverage of CareTrust REIT with a rating of Mkt Outperform and set a new price target of $44.00
BMO Capital Markets upgraded CareTrust REIT from Market Perform to Outperform and set a new price target of $43.00
UBS initiated coverage of CareTrust REIT with a rating of Buy and set a new price target of $42.00
Conference Call Scheduled for Friday, February 13, 2026 at 1:00 pm ET CareTrust REIT, Inc. (NYSE:CTRE) today reported operating results for the quarter and year ended December 31, 2025, as well as other recent events. For the full year 2025, CareTrust reported: Net income attributable to CareTrust of $320.5 million and net income per diluted weighted average share of $1.57, an increase of $0.77, or 96%, over the prior year; Normalized FFO attributable to CareTrust of $359.7 million and Normalized FFO per diluted weighted average share of $1.76, an increase of $0.26, or 17% over the prior year; Normalized FAD attributable to CareTrust of $360.0 million and Normalized FAD per dil
CareTrust REIT, Inc. (NYSE:CTRE) ("CareTrust") announced today that it plans to release its fourth quarter and full year 2025 financial results after the U.S. markets close on Thursday, February 12, 2026. Representatives of CareTrust's management team will host a conference call to discuss the results and other current matters the following day. Conference Call CareTrust invites current and prospective investors to listen to the call on Friday, February 13, 2026, at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time). The live audio webcast of the earnings conference call will be available on the Investors section of CareTrust's website at investor.caretrustreit.com/events-and-presentation
CareTrust REIT, Inc. (NYSE:CTRE) reported today the tax status of its 2025 dividends paid to shareholders. Details on the classifications of the dividends are included in the table below: DISTRIBUTIONS ON CARETRUST COMMON STOCK Box 1a Box 1b Box 2a Box 2b Box 3 Box 5 Record Date Payment Date Distribution Per Share Taxable Distribution Per Share Ordinary Dividend Qualified Dividend (Included in Box 1a) Capital Gain Distr. Unrecap. Section 1250 Gain (Included in Box 2a) Non-Dividend Distributions Section 199A Dividend 12/31/24 01/15/25
4 - CareTrust REIT, Inc. (0001590717) (Issuer)
4 - CareTrust REIT, Inc. (0001590717) (Issuer)
4 - CareTrust REIT, Inc. (0001590717) (Issuer)
8-K - CareTrust REIT, Inc. (0001590717) (Filer)
424B5 - CareTrust REIT, Inc. (0001590717) (Filer)
8-K - CareTrust REIT, Inc. (0001590717) (Filer)
SC 13G/A - CareTrust REIT, Inc. (0001590717) (Subject)
SC 13G/A - CareTrust REIT, Inc. (0001590717) (Subject)
SC 13G/A - CareTrust REIT, Inc. (0001590717) (Subject)
Conference Call Scheduled for Friday, February 13, 2026 at 1:00 pm ET CareTrust REIT, Inc. (NYSE:CTRE) today reported operating results for the quarter and year ended December 31, 2025, as well as other recent events. For the full year 2025, CareTrust reported: Net income attributable to CareTrust of $320.5 million and net income per diluted weighted average share of $1.57, an increase of $0.77, or 96%, over the prior year; Normalized FFO attributable to CareTrust of $359.7 million and Normalized FFO per diluted weighted average share of $1.76, an increase of $0.26, or 17% over the prior year; Normalized FAD attributable to CareTrust of $360.0 million and Normalized FAD per dil
CareTrust REIT, Inc. (NYSE:CTRE) ("CareTrust") announced today that it plans to release its fourth quarter and full year 2025 financial results after the U.S. markets close on Thursday, February 12, 2026. Representatives of CareTrust's management team will host a conference call to discuss the results and other current matters the following day. Conference Call CareTrust invites current and prospective investors to listen to the call on Friday, February 13, 2026, at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time). The live audio webcast of the earnings conference call will be available on the Investors section of CareTrust's website at investor.caretrustreit.com/events-and-presentation
CareTrust REIT, Inc. (NYSE:CTRE) reported today the tax status of its 2025 dividends paid to shareholders. Details on the classifications of the dividends are included in the table below: DISTRIBUTIONS ON CARETRUST COMMON STOCK Box 1a Box 1b Box 2a Box 2b Box 3 Box 5 Record Date Payment Date Distribution Per Share Taxable Distribution Per Share Ordinary Dividend Qualified Dividend (Included in Box 1a) Capital Gain Distr. Unrecap. Section 1250 Gain (Included in Box 2a) Non-Dividend Distributions Section 199A Dividend 12/31/24 01/15/25
CareTrust REIT, Inc. (NYSE:CTRE) ("CareTrust" or the "Company") announced today the appointment of Greg Stapley to the Company's Board of Directors (the "Board"), effective January 1, 2026. Mr. Stapley brings a distinguished record of leadership and deep institutional knowledge of the healthcare real estate sector, having previously served as CareTrust's President and Chief Executive Officer from the Company's inception in 2014 to 2022. Prior to his tenure at the helm of CareTrust, Mr. Stapley was a co-founder of The Ensign Group, Inc. ("Ensign"), serving as its General Counsel and later as Executive Vice President until leading the spin-off of CareTrust from Ensign. Before Ensign, Mr. St
The Board of Directors of CareTrust REIT, Inc. (NYSE:CTRE) announced the appointment of Lauren Beale as Chief Accounting Officer (CAO), effective as of January 1, 2025. Ms. Beale becomes the company's first CAO after serving in different leadership roles since the inception of CareTrust. "On behalf of the Board and all of us at CareTrust, I express our gratitude for the tremendous impact Lauren has had on building the company since the beginning," said Chief Executive Officer, Dave Sedgwick. Bill Wagner, Chief Financial Officer, said, "Lauren's appointment to CAO is the natural result of years of tireless effort to help build CareTrust from scratch." The company also welcomes Tri Tran a
The Board of Directors of CareTrust REIT, Inc. (NYSE:CTRE) announced today the appointment of James Callister as Chief Investment Officer, to be effective as of December 31, 2022. Mr. Callister will succeed Mark Lamb, who will be leaving the company after a transition period to pursue entrepreneurial opportunities. Mr. Callister currently serves as CareTrust's Executive Vice President. "On behalf of the Board and all of us at CareTrust, I express our admiration and gratitude for the tremendous impact Mark has had on building the company since the beginning," said Chief Executive Officer, Dave Sedgwick. "Mark has always been a true partner and friend and we wish him continued success in the